Impact of STAT3 phosphorylation on the clinical effectiveness of anti-egfr-based therapy in patients with metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 12, Issue 1, 2013, Pages 28-36

  Dobi, Erion ^a,b   Monnien, Franck ^a   Kim, Stefano ^a   Ivanaj, Arben ^c   N'Guyen, Thiery ^a   Demarchi, Martin ^a   Adotevi, Olivier ^a,b   Thierry Vuillemin, Antoine ^a   Jary, Marie ^a   Kantelip, Bernadette ^a   Pivot, Xavier ^a,b   Godet, Yann ^b   Degano, Severine Valmary ^a   Borg, Christophe ^a,b,d  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^c UNIVERSITY HOSPITAL CENTER MOTHER TERESA   (Albania)

^d UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

Author keywords

Cetuximab; Colorectal cancer; EGFR; KRAS; Signal transducer and activator of transcription 3 (STAT3)

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; STAT3 PROTEIN;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; CONTROLLED STUDY; DRUG ERUPTION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RETROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT RESPONSE; WILD TYPE;

EID: 84874691026     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2012.09.002     Document Type: Article

References (36)

1. A. Jemal, R. Siegel, E. Ward Cancer statistics CA Cancer J Clin 59 2009 225 249
2. H. Hurwitz, L. Fehrenbacher, W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
3. E. Van Cutsem, C.H. Köhne, I. Láng Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status J Clin Oncol 29 2011 2011 2019
4. J.Y. Douillard, S. Siena, J. Cassidy Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study J Clin Oncol 28 2010 4697 4705
5. E. Van Cutsem, M. Peeters, S. Siena Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J Clin Oncol 25 2007 1658 1664
6. A. Lièvre, J.B. Bachet, D. Le Corre KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer Cancer Res 66 2006 3992 3995
7. F. Di Fiore, F. Blanchard, F. Charbonnier Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy Br J Cancer 96 2007 1166 1169
8. C.S. Karapetis, S. Khambata-Ford, D.J. Jonker K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 2008 1757 1765
9. R.G. Amado, M. Wolf, M. Peeters Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 2008 1626 1634
10. H. Yu, H. Jove The STATs of cancer - new molecular targets come of age Nat Rev Cancer 4 2004 97 105
11. D.E. Levy, C.K. Lee What does Stat3 do? J Clin Invest 109 2002 1143 1148
12. J.F. Bromberg, C.M. Horvath, D. Besser Stat3 activation is required for cellular transformation by v-src Mol Cell Biol 18 1998 2553 2558
13. R. Bedel, A. Thiery-Vuillemin, C. Grandclement Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells Cancer Res 71 2011 1615 1626
14. B. Barré, A. Vigneron, O. Coqueret The STAT3 transcription factor is a target for the Myc and riboblastoma proteins on the Cdc25A promoter J Biol Chem 280 2005 15673 15681
15. K. Leslie, C. Lang, G. Devgan Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3 Cancer Res 66 2006 2544 2552
16. T. Shirogane, T. Fukada, J.M. Muller Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis Immunity 11 1999 709 719
17. T. Kusaba, T. Nakayama, K. Yamazumi Activation of STAT3 is a marker of poor prognosis in human colorectal cancer Oncol Rep 15 2006 1445 1451
18. J. Bollrath, T.J. Phesse, V.A. von Burstin gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis Cancer Cell 15 2009 91 102
19. T. Morikawa, Y. Baba, M. Yamauchi STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers Clin Cancer Res 17 2011 1452 1462
20. A. Vigneron, E. Gamelin, O. Coqueret The EGFR-STAT3 oncogenic pathway up-regulates the Eme1 endonuclease to reduce DNA damage after topoisomerase I inhibition Cancer Res 68 2008 815 825
21. J.R. Grandis, S.D. Drenning, A. Chakraborty Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro J Clin Invest 102 1998 1385 1392
22. B. Barré, A. Vigneron, N. Perkins The STAT3 oncogene as a predictive marker of drug resistance Trends Mol Med 13 2007 4 11
23. S. Magnin, E. Viel, A. Baraquin A multiplex SNaPshot assay as a rapid method for detecting KRAS and BRAF mutations in advanced colorectal cancers J Mol Diagn 13 2011 485 492
24. C. Bokemeyer, I. Bondarenko, J.T. Hartmann Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study Ann Oncol 22 2011 1535 1546
25. D. Cunningham, Y. Humblet, S. Siena Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345
26. R. Wong, D. Cunningham Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies J Clin Oncol 26 2008 5668 5670
27. J.F. Bromberg, M.H. Wrzeszczynska, G. Devgan Stat3 as an oncogene Cell 98 1999 295 303
28. G. Niu, K.L. Wright, M. Huang Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis Oncogene 21 2002 2000 2008
29. S. Alas, B. Bonavida Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs Cancer Res 61 2001 5137 5144
30. S. Alas, B. Bonavida Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis Clin Cancer Res 9 2003 316 326
31. - stem cell-like breast cancer cells in human tumors J Clin Invest 121 2011 2723 2735
32. C.J. Creighton, X. Li, M. Landis Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features Proc Natl Acad Sci U S A 106 2009 13820 13825
33. X. Li, M.T. Lewis, J. Huang Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy J Natl Cancer Inst 100 2008 672 679
34. N. Diaz, S. Minton, C. Cox Activation of STAT3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression Clin Cancer Res 12 2006 20 28
35. S. Ruff-Jamison, Z. Zhong, Z. Wen Epidermal growth factor and lipopolysaccharide activate Stat3 transcription factor in mouse liver J Biol Chem 269 1994 21933 21945
36. A.J. Weickhardt, T.J. Price, G. Chong Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer J Clin Oncol 30 2012 1505 1512